European investment firm Forbion Capital Partners has announced the closing of a €190 million ($240m) life sciences investment fund. The VC--which has offices in the Netherlands and Germany--aims to invest most of the money in Europe and the remainder in North America and Israel. Forbion will focus its investments on private companies developing novel drugs, medical devices and diagnostics for high or unmet medical needs.
According to Reuters, Forbion is considering an investment in Amsterdam Molecular Therapeutics, which is awaiting EMA approval of its lead product Glybera. Forbion Managing Partner Bart Bergstein also says his firm is mulling two stock listings of biotechs it had previously invested in.
"We are very pleased to have raised such a substantial amount as fundraising conditions have never been more challenging" notes Bergstein in a statement. "Given that only few venture players have active funds to commit from, we currently see many highly attractive assets from an increasingly rich deal flow. We are therefore confident that both new funds could be at least as successful as FCF I."
- take a look at Forbion's release
- see the report from Reuters